Detection of human cytomegalovirus DNA in perilymph of patients with sensorineural hearing loss using real-time PCR

2002 ◽  
Vol 69 (1) ◽  
pp. 72-75 ◽  
Author(s):  
Saiko Sugiura ◽  
Tetsushi Yoshikawa ◽  
Yukihiro Nishiyama ◽  
Yoshihiro Morishita ◽  
Eisuke Sato ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Real Time ◽  
Human Cytomegalovirus ◽  
Real Time Pcr ◽  
Sensorineural Hearing

scholarly journals Congenital Human Cytomegalovirus Infection Inducing Sensorineural Hearing Loss

2021 ◽  
Vol 12 ◽  
Author(s):  
Wenwen Xia ◽  
Hui Yan ◽  
Yiyuan Zhang ◽  
Congcong Wang ◽  
Wei Gao ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Human Cytomegalovirus ◽  
Cytomegalovirus Infection ◽  
Hcmv Infection ◽  
Spiral Ganglion ◽  
Sensorineural Deafness ◽  
Sensorineural Hearing ◽  
Inflammatory Factors ◽  
Congenital Hcmv Infection

Human cytomegalovirus (HCMV) is the primary cause of congenital infections. Despite its clinical significance, congenital HCMV infection is frequently overlooked clinically since most affected infants are asymptomatic. Sensorineural hearing loss (SNHL) is one of the most widely known disorders caused by congenital HCMV infection. The potential mechanism, however, remains unknown to date. The mechanism by which congenital HCMV infection induces sensorineural deafness has been partly characterized, leading to advancements in diagnosis, therapy, and prevention strategies. HCMV-induced hearing loss primarily involves immune responses, the release of inflammatory factors by natural killer (NK) cells, apoptosis of cochlear spiral ganglion, and potential changes due to vascular dysfunction. The diagnosis of HCMV induced SNHL includes serological examination to mothers, imaging, and amniotic fluid examination. Ganciclovir, mainly used for antiviral therapy and behavioral prevention, can, to some degree, prevent congenital HCMV infection. The role of HCMV infection in hearing loss needs further investigation since the mechanism of hearing loss caused by cytomegalovirus infection is not well understood. Although some advancement has been made in diagnosing and treating SNHL, more improvement is needed. A comprehensive understanding of cytomegalovirus’s pathogenesis is of key importance for preventing, diagnosing, and treating SNHL.

Detection of Herpesvirus DNAs in Perilymph Obtained from Patients with Sensorineural Hearing Loss by Real-Time Polymerase Chain Reaction

2004 ◽  
Vol 114 (12) ◽  
pp. 2235-2238 ◽  
Author(s):  
Saiko Sugiura ◽  
Tetsushi Yoshikawa ◽  
Yukihiro Nishiyama ◽  
Yoshihiro Morishita ◽  
Eisuke Sato ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Real Time ◽  
Sensorineural Hearing ◽  
Chain Reaction ◽  
Polymerase Chain

Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up

2008 ◽  
Vol 123 (4) ◽  
pp. 391-396 ◽  
Author(s):  
A Lackner ◽  
A Acham ◽  
T Alborno ◽  
M Moser ◽  
H Engele ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Human Cytomegalovirus ◽  
Cytomegalovirus Infection ◽  
Sensorineural Hearing ◽  
Congenital Cytomegalovirus Infection ◽  
Newborn Period ◽  
Congenital Cytomegalovirus ◽  
Ganciclovir Therapy

AbstractBackground:Congenital cytomegalovirus infection is the leading identified nongenetic cause of congenital sensorineural hearing loss. Most of the infections are asymptomatic but may be detected from umbilical cord vein and/or newborn serum positivity for human cytomegalovirus immunoglobulin M, and from urine positivity (on polymerase chain reaction) for human cytomegalovirus deoxyribonucleic acid in the newborn period. Children infected by cytomegalovirus may later develop sensorineural hearing loss. In symptomatically infected infants, ganciclovir therapy administered in the neonatal period prevents hearing deterioration. However, preventative therapy of asymptomatic congenital cytomegalovirus disease with ganciclovir is controversial, as side effects such as severe neutropenia may occur during treatment.Methods:The study population consisted of 23 asymptomatic children with congenital cytomegalovirus infection. Twelve children were treated just after diagnosis of cytomegalovirus infection in the newborn period, with ganciclovir 10 mg/kg bodyweight for 21 days. The other 11 children were observed without therapy. Over a four to 10 year follow-up period, we evaluated all the children's hearing status using pure tone audiometry.Results:All 23 children had normal sensorineural hearing at one year follow up. Five of the 23 children (21.7 per cent) were lost to follow up over the four to 11 year follow-up period. Of the remaining 18 children, sensorineural hearing loss occurred in two (11.1 per cent). Neither child had been treated with ganciclovir in the newborn period. An eight-year-old boy showed bilateral high frequency loss and a 10-year-old girl showed severe unilateral sensorineural hearing loss. In the ganciclovir-treated group (nine children), none showed sensorineural hearing loss. During ganciclovir therapy, moderate neutropenia occurred as a side effect in two out of 12 (16.6 per cent) treated children. Speech and general development were normal in all children.Conclusion:Asymptomatic congenital cytomegalovirus infection is likely to be a leading cause of sensorineural hearing loss in young children. Intravenous ganciclovir therapy seems to offer a medical option to prevent subsequent sensorineural hearing loss. Further studies including a greater number of children are needed. Cytomegalovirus screening models are mandatory if medical therapy is to be implemented in time.

Sign in / Sign up

Export Citation Format

Share Document